Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Acetylation pharmacogenetics: experimental models for human toxicity.

W W Weber

    Federation Proceedings
    |May 15, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Pharmacogenetic tactics and strategies: implications for paediatrics.

    Paediatric drugs·2002
    Same author

    The legacy of pharmacogenetics and potential applications.

    Mutation research·2001
    Same author

    Effect of pharmacogenetics on medicine.

    Environmental and molecular mutagenesis·2001
    Same author

    Pharmacogenetics of the arylamine N-acetyltransferases: a symposium in honor of Wendell W. Weber.

    Drug metabolism and disposition: the biological fate of chemicals·2000
    Same author

    Characterization of naturally occurring and recombinant human N-acetyltransferase variants encoded by NAT1.

    Molecular pharmacology·2000
    Same author

    Populations and genetic polymorphisms.

    Molecular diagnosis : a journal devoted to the understanding of human disease through the clinical application of molecular biology·2000

    Genetic variations in acetylation influence drug metabolism and toxicity. Animal models, particularly rabbits, reveal slow acetylators are more susceptible to certain drug toxicities, challenging previous assumptions about rapid acetylators.

    Area of Science:

    • Pharmacogenetics
    • Toxicology
    • Metabolism

    Background:

    • Hereditary acetylation polymorphisms are known in rabbits, mice, and hamsters.
    • These polymorphisms significantly impact the metabolism and toxicity of arylamines and hydrazines.
    • The rabbit acetylation polymorphism closely mirrors human genetic variations.

    Purpose of the Study:

    • To investigate the influence of acetylation polymorphisms on drug metabolism and toxicity using animal models.
    • To examine the differential susceptibility of rapid and slow acetylators to specific drug-induced toxicities.
    • To explore the mechanisms of DNA damage induced by arylamines and hydrazines in relation to acetylation status.

    Main Methods:

    • Utilizing rabbit models with known N-acetyltransferase polymorphisms.

    Related Experiment Videos

  • Administering monoacetylhydrazine and isoniazid (INH) to assess toxicity in rapid and slow acetylators.
  • Exposing cultured hepatocytes from rapid and slow acetylators to arylamines and hydrazines to evaluate DNA damage and toxicity.

    • Main Results:

    • Monoacetylhydrazine metabolism is polymorphic in rabbits, with differing sensitivities in rapid and slow acetylators.
    • Slow acetylators exhibit increased sensitivity to isoniazid-induced central nervous system toxicity.
    • Hydralazine causes DNA damage in slow acetylator hepatocytes, while 2-aminofluorene and benzidine induce damage in rapid acetylator hepatocytes.

    Conclusions:

    • Acetylation polymorphisms play a crucial role in determining individual responses to drugs and environmental toxins.
    • Rabbit models provide valuable insights into human pharmacogenetics and toxicity related to arylamines and hydrazines.
    • Findings challenge the established view on rapid acetylators and isoniazid hepatotoxicity, highlighting differential risks based on acetylation status.